Exploring CPP Enhanced Hypoxia Targeting: An Approach Using Radiolabeled 2-nitroimidazole TAT Conjugate.

Area of Science:

• Biomedical Engineering
• Molecular Imaging
• Drug Delivery

Background:

• Cell-penetrating peptides (CPPs) facilitate intracellular delivery.
• Targeting tumor hypoxia is crucial for effective cancer therapy.
• 2-nitroimidazole derivatives are hypoxia-sensitive moieties.

Purpose of the Study:

• To develop and evaluate a novel radiolabeled CPP conjugate for targeting tumor hypoxia.
• To assess the in vitro and in vivo performance of the conjugate.

Main Methods:

• Synthesis of iodine-125 labeled 2-nitroimidazole conjugated TAT peptide ([125I]I-TAT-2-NIM).
• In vitro studies using CHO cells under hypoxic and normoxic conditions.
• In vivo studies in tumor-bearing models to evaluate tumor uptake and retention.

Main Results:

• [125I]I-TAT-2-NIM showed significantly higher uptake in hypoxic cells compared to [125I]I-TAT in vitro.
• Hypoxia negatively influenced the cellular uptake of radiolabeled TAT peptides.
• In vivo, [125I]I-TAT-2-NIM demonstrated tumor uptake and retention with a tumor/muscle ratio > 2.

Conclusions:

• The 2-nitroimidazole moiety enhances hypoxic cell targeting of CPPs.
• Hypoxia-induced reduction in CPP uptake presents a limitation for hypoxia-targeted delivery.
• Further optimization is needed to overcome hypoxia's negative impact on CPPs for effective tumor targeting.